Skip to main content

Rapivab FDA Approval History

FDA Approved: Yes (First approved December 19, 2014)
Brand name: Rapivab
Generic name: peramivir
Dosage form: Injection
Company: BioCryst Pharmaceuticals, Inc.
Treatment for: Influenza

Rapivab (peramivir) is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza.

Development timeline for Rapivab

DateArticle
Feb  3, 2021Approval BioCryst Announces FDA Approval of Supplemental New Drug Application for Rapivab Expanding Patient Population to Include Children Six Months and Older
Sep 21, 2017Approval BioCryst's Rapivab (peramivir injection) Receives FDA Approval for a Pediatric Indication
Dec 22, 2014Approval FDA Approves Rapivab (peramivir) to Treat Influenza Infection
Sep 10, 2014BioCryst Announces Rapivab (peramivir injection) Trial Results for the Treatment of Influenza
Feb 25, 2014BioCryst Announces Peramivir NDA Acceptance by the FDA

See also

Rapivab (peramivir) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer